Editor's key points † High inspired oxygen supplementation during anaesthesia may be associated with adverse outcomes. † This post hoc analysis of the PROXI trial evaluated the association between FI O 2 = 0.8 or FI O 2 = 0.3 and cancer incidence or recurrence after a median time of 4 yr. † Although the incidence of cancer was similar, higher mortality was observed in the high inspired O 2 group, and shorter cancer-free survival.
1 2 because formation of reactive oxygen species (ROS) may damage cell components including DNA if the ROS are not neutralized by antioxidant systems. An overload of oxygen may thus not be desirable, 4 and recent studies have indicated increased morbidity and mortality with excess oxygen administration in various emergency medical conditions. 5 -8 On the other hand, oxygen supplementation is often used during general anaesthesia, where an impairment of cardiovascular and pulmonal function can compromise oxygen delivery. 9 A high perioperative inspiratory oxygen fraction (FI O 2 ) of 0.80 has therefore been proposed to prevent wound infection, and some randomized trials have shown benefit, 10 -12 whereas others, including the PROXI trial, have not. 13 -16 In the PROXI trial, 30 day mortality tended to be higher when 80% oxygen was given during laparotomy compared with 30% oxygen, and a subsequent analysis detected increased long-term mortality with hyperoxia, predominantly in patients undergoing cancer surgery. 17 The effect of hyperoxia on cancer development is, however, sparsely elucidated, although high levels of oxygen in addition to DNA damage induce angiogenesis and may increase erythropoietin production, which is a potent cellular growth factor. 3 18 19 Angiogen-could thus lead to growth of new or remaining tumour cells after otherwise curative surgery. Thus, we found it important to evaluate the risk of developing new or subsequent cancers after exposure to perioperative hyperoxia. The aim of this post hoc study of the PROXI trial 13 was to assess the possible association between an FI O 2 of 0.80 during and after laparotomy on the occurrence of a subsequent, new or recurrent, cancer over a 4 yr follow-up period.
Methods
Approval was obtained for the PROXI trial and this follow-up study from the regional Ethics Committee (The Capital Region, Denmark, KF 02 306766), the Danish Medicines Agency (registered with EudraCT no. 2006-001710-32), and the Danish Data Protection Agency. 13 20 After written informed consent, 1386 patients were included in 14 Danish hospitals between October 8, 2006 , and October 6, 2008. Patients were aged 18 yr or older, and undergoing elective or emergency laparotomy. Exclusion criteria were: surgery performed under general anaesthesia within the preceding 30 days, chemotherapy for malignant disease within the preceding 3 months, inability to give informed consent, and preoperative arterial oxygen saturation below 90% without supplemental oxygen. 13 20 Patients were randomized to either the 80% or the 30% oxygen group with stratification for: centre, diabetes mellitus, elective or emergency surgery, and body mass index (BMI) (,30 or ≥30 kg m 22 ). 20 A trial protocol was used to standardize key elements of perioperative care, including temperature and glucose control, prophylactic antibiotics administration, epidural analgesia, general anaesthesia without nitrous oxide, and normovolaemic fluid therapy. 20 The interventions consisted of an FI O 2 of 0.80 or 0.30 given after tracheal intubation and until tracheal extubation. For the first 2 postoperative hours, the allocated oxygen concentration was delivered through a non-rebreathing face mask with reservoir with a flow of either 14 litres of O 2 and 2 litres of air per minute or 2 litres of O 2 and 14 litres of air per minute. The intervention was blinded to patients, surgeons, the staff on the wards, outcome assessors, and statisticians. 20 Extended follow-up was performed on September 28, 2011, where data were collected from the Danish National Patient Registry, the Danish Cancer Registry, the Danish Cause of Death Registry, and the Danish Patobank (collecting all histological specimens in Denmark). There are mandatory registration to all databases from all Danish hospitals, and all Danish citizens are registered with a unique 10 digit number. 21 Cancer diagnoses were classified according to the ICD-10 and graded with the tumour, node, and metastasis classification (TNM), and underwent extensive validation at the Danish Cancer Registry for duplicate information and consistency. In cases with multiple previous cancers, we classified T, N, and M as the worst grade, respectively. Metastatic spread was defined as any N.0 or any M¼1. Patients with a cancer diagnosis, but unknown N and M status were classified as having no metastatic spread. defined readmission as the first hospital admission after final discharge. Diagnosis codes for readmission were classified according to the primary ICD-10 and the secondary ICD-10 codes. Cancer-free survival was the time from index surgery to the first of the following events: death, new cancer diagnosis, or new histological specimen showing any malignant neoplasm within the longest follow-up period until September 28, 2011. As other explorative outcomes, we described histological type of new cancer specimen and cause of death, which was classified according to the primary and secondary ICD-10 codes for cause of death listed on the death certificate. The Danish Cause of Death Registry has a 1-2 yr delay for data validation, and the follow-up date for cause of death was therefore December 31, 2009.
Statistical analysis
The statistical analyses were planned before data were available (NCT01723280). The primary and secondary outcomes were first investigated in the Kaplan-Meier plots of the survival curves, stratified for 80% vs 30% oxygen and additionally on cancer status at the time of index surgery. Thereafter, the primary and secondary outcomes were analysed in the Cox proportional hazards models in which a hazard ratio (HR) measured the independent effect of 80% vs 30% oxygen. These analyses were done both unadjusted and adjusted for the following design and stratification variables: 13 22 elective or emergency surgery, diabetes mellitus, BMI (,30 or ≥30 kg m
22
), trial site, daily smoking, age (,40 or ≥40 yr), alcohol consumption .48 g day 21 , ASA physical status score, cardiovascular disease other than hypertension, perioperative blood transfusion, and cancer status at the time of index surgery. The adjusted HR was used in the primary analyses. Time between surgery and events was compared using the Wilcoxon rank-sum test. Subgroup analyses were performed according to patients with no cancer, localized cancer, or metastatic cancer at baseline. Additionally, two sensitivity analyses were planned: one in which follow-up for the primary outcome was December 31, 2009 , where complete data sets from the Danish Cancer Registry and the Danish Patobank were available, and another which evaluated the primary outcome across subgroups when patients with unknown status for disseminated cancer disease were classified as having metastasized cancer.
The original sample size calculation is described elsewhere. 20 All intervention effect estimates were analysed according to the intention-to-treat principle and reported with 95% confidence interval (CI) and a two-sided P,0.05 was considered statistically significant. Analyses were performed using SAS for Windows, version 9.3 (SAS Institute, Inc., Cary, NC, USA).
Results
The PROXI trial included 1386 patients, and at follow-up, six patients were no longer Danish citizens, and three patients could not be located in the patient registries. Complete data were obtained from 1377 patients (99.4%) after a median follow-up of 3.9 (range 2.9-5.0) yr with comparable patient characteristics at baseline in the two groups (Table 1) . There were 57 new cancer diagnoses and 782 histological specimens in 290 patients after index surgery showing malignant neoplasia. The primary composite outcome of either a subsequent cancer diagnosis or a new histological cancer specimen occurred in 140 of 678 patients (21%) in the 80% oxygen group vs 150 of 699 patients (21%) patients assigned to 30% oxygen; HR 1.06 (95% CI 0.84, 1.34), P¼0.62 (Table 2 ). There were no significant differences in new histological malignancy or readmission for cancer (Tables 2 and 3 ). Long-term mortality was significantly higher in the 80% oxygen group, with an HR of 1.29 (95% CI 1.05, 1.58), P¼0.02 (Table 2) , and cancer-free survival was lower in the 80% oxygen group with an HR for death or cancer of 1.19 (95% CI 1.01, 1.42), P¼0.04 (Fig. 1 , Table 2 ). In patients meeting the composite outcome, the time between surgery and new cancer was shorter in 80% oxygen group, median 335 vs 434 days in the 30% oxygen group, P¼0.047 (Table 4) .
In the subgroup analysis according to baseline cancer status, the largest differences were found in patients with localized cancer. The median time between surgery and the primary outcome of new cancer was 390 and 567 days (P¼0.03) in the 80% and 30% oxygen group, respectively. Cancer-free survival was not significantly different in patients with localized cancer; HR for death or cancer 1.29 (95% CI 0.97, 1.72), P¼0.08 (Fig. 2, Table 2 ).
In the first sensitivity analysis, where follow-up was the latest time with available data sets in the Danish Patobank and the Danish Cancer Registry, the primary outcome was fulfilled in 118 of 678 patients (17%) vs 109 of 699 patients (16%) in the 80% and 30% oxygen group, respectively, HR 1.17 (95% CI 0.89, 1.52), P¼0.26. Cancer-free survival was shorter in the 80% oxygen group, HR for death or cancer 1.24 (95% CI 1.02, 1.50), P¼0.03.
The second sensitivity analysis, in which unknown baseline cancer dissemination was classified as metastatic disease, showed a slightly larger difference in the primary outcome 47 of 175 patients (27%) vs 37 of 181 patients (20%), HR 1.56 (95% CI 1.01, 2.41), P¼0.04, and a slightly larger difference in cancer-free survival, HR for death, or cancer 1.43 (95% CI 1.04, 1.98), P¼0.03, when comparing 80% with 30% oxygen in patients with localized disease.
As explanatory analysis, we performed a survival analysis with new cancer as censoring event in order to investigate whether a higher cancer occurrence may explain the previously found higher mortality (Table 2) . This analysis showed a slightly more pronounced risk of long-term mortality; HR 1.40 (95% CI 1.08, 1.80).
Discussion
In this long-term follow-up study of new or recurrent cancers after 80% vs 30% oxygen was given during abdominal surgery, we found that the overall frequency of cancers were similar. However, the time to new cancer and cancer-free survival was shorter in the 80% oxygen group, with the largest burden of early cancer and death among patients with localized disease at baseline.
This first description of association between supplemental oxygen and subsequent cancers with almost complete followup rate (99.4%) of a randomized trial are the primary strengths of our study together with the high validity of data in the national patient registries in Denmark, 21 which receive mandatory reporting from all hospitals based on a unique ID for every patient.
The extended follow-up of our trial comes with limitations as well. The outcomes were defined after enrolment of the 1400 patients in the trial, a sample size calculated to evaluate surgical site infection. On the other hand, we defined and published the research plan for this follow-up study before cancer data were extracted. We had 86% power to detect an HR of 1.19 for cancer-free survival with 5% type 1 error risk based on our subjects included over 730 days with additional follow-up for 1087 days after inclusion of last patient, the median cancerfree survival time being 363 days in the control group, but the power to detect an HR of 1.06 for our primary outcome is much lower. Although an HR of 1.19 for cancer-free survival must be considered important, smaller differences are also clinically relevant, and the power to explore this in the subgroups is even smaller. Secondly, we could not measure the distribution between recurrent cancers and new cancers among our primary outcome, because information about peroperative margin-free resection was not available, but our composite primary outcome is the most sensitive measure of new cancer burden for the patient. The sensitivity analysis with the shortest follow-up did in fact result in marginally larger differences between the 80% and 30% oxygen group. Thirdly, the patient population underwent a broad range of elective and emergency laparotomy procedures, and only some of the procedures involved manipulation of a tumour, which could influence the risk of micrometastases and cancer recurrence. 23 24 On the other hand, although tumour stage was not available, we had thorough knowledge of all known previous and current cancers, and those were evenly distributed between the groups. We observed a virtually identical frequency of new cancers in the 80% and 30% oxygen group, but cancer-free survival and time to cancer were shorter in the 80% oxygen group, recognizing that time to new cancer is an explanatory outcome and a much lower P-value is needed to achieve firm evidence. 25 We have previously reported increased long-term mortality in our 80% oxygen group, 17 and it is therefore likely that the problem of competing outcomes could influence the interpretation of certain results, that is: the patients in the 30% oxygen group live longer and have thus a higher risk of developing a new cancer in the follow-up period, which again can mask a potentially increased frequency of cancers in the 80% oxygen group. Therefore, to alleviate this problem, we chose to analyse the primary and secondary outcomes in a model for time-to-event data-the Cox regression model. Some of our findings oppose cancer as causing the increased mortality, because the point estimate of HR of time to death with cancer as censoring event (1.40) was in fact slightly higher than the HR of time to death (1.29). This suggests that other explanations than new cancer should explain the observed increased mortality in the 80% oxygen group. We could furthermore not identify a specific type of histology that was more vulnerable to perioperative hyperoxia. Nevertheless, we found that patients in the localized subgroup, that is, patients with previous or current cancer at the time of index surgery who has no lymph node or distant metastases, may be somewhat vulnerable to perioperative hyperoxia. Subsequent cancers in this subgroup represent recurrence or a new cancer, and we found statistically nonsignificant hazards ratios of 1.31 for new cancer and 1.29 for cancer or death, and these differences were in fact statistically significant in the sensitivity analysis with unknown N and M status classified as metastatic disease. Further, if new cancer developed in the localized subgroup, this occurred at a median of 177 days earlier in the 80% oxygen group.
A number of aspects are important during surgery for the course of a localized cancer, because manipulation of the tumour may result in release of tumour cells to the blood or lymph stream 24 and micrometastases may be present in onequarter of lymph node-negative patients. 23 The progression of such minimal residual disease is dependent on intact immune function, and a number of perioperative factors are in fact depressing the cell-mediated immune system, and increasing angiogenesis and growth factors that promote local and distant growth of malignant cells. 24 Supplemental perioperative oxygen has a strong positive effect on angiogenesis, 18 whereas the effects on growth factor stimulation and the local immune system are not fully clarified, 19 26 leading to hypotheses with tumour suppression and tumour progression. 19 Hyperoxia may increase the production of erythropoietin, a potent cellular growth factor, 9 27 and the formation of ROS in the hyperoxic environment may promote DNA damage. 3 19 26-29 The sum of angiogenesis, erythropoietin production, and oxidative stress could thus lead to growth of minimal residual disease after otherwise curative surgery.
Other studies have investigated long-term outcomes after anaesthesia, and a 3.5 yr follow-up of the ENIGMA trial, 30 comparing 70% nitrous oxide with 80% oxygen, found no significant difference in long-term mortality. The investigated interventions may, however, have resulted in similar perioperative harm. The frequency of new cancers and cancer-free survival in our study are comparable with those found in studies on epidural analgesia to prevent cancer recurrence. 31 32 Recently, major concerns have been raised with hyperoxia in emergency medical settings. 4 A randomized trial of patients with exacerbation of chronic obstructive pulmonary disease found increased mortality with prehospital hyperoxia. 5 Large retrospective studies have found higher morbidity and mortality when hyperoxia is present after resuscitation from cardiac arrest and traumatic brain injury, 6 7 and a Cochrane review suggest increased mortality after myocardial infarction with supplemental oxygen therapy. 8 Our study can generate new hypotheses, but not prove causality between perioperative hyperoxia, subsequent cancers, and long-term mortality. Furthermore, other hypotheses for the larger long-term mortality with 80% oxygen also deserve attention, such as increased risk of cardiovascular disease. Hyperoxia result in perioperative arterial vasoconstriction and reduced coronary blood flow, 33 34 and together with oxidative stress and DNA damage, this could lead to accelerated atherosclerosis or plaque rupture.
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We thus recommend avoiding administration of inspiratory oxygen fractions higher than what is needed to maintain normal arterial oxygen saturation until a benefit has been documented.
In conclusion, no difference in new or recurrent cancers was found in patients given 80% or 30% oxygen during and
